Citations

Clear

2303 citation(s) found for "Yu, Edward".

S37 Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: U-ENDURE Phase 3 Results
Lacerda, Ana P. , D’Haens, Geert , Reinisch, Walter, Louis, Édouard , Chen, Minhu , Boland, Brigid S. , Dubcenco, Elena, Feng, Tian, Panés, Julián , Loftus, Edward V. , Peyrin‐Biroulet, Laurent , Panaccione, Remo , Reinisch, Walter , Louis, Edouard , Nakase, Hiroshi , Begun, Jakob , Liu, Jianzhong , Mohamed, Mohamed‐Eslam F. , Feng, Tian, Colombel, Jean‐Frédéric

Mayo Clinic

American Journal of Gastroenterology | December 5, 2022 | Volume: 117 | Issue: 12S | Pages: S10-S10

10.14309/01.ajg.0000897656.25080.34 Get It

S99 Upadacitinib in the Treatment of Ulcerative Colitis. Initial Real-World Experience From a Tertiary Care Center
Chowla, Navreet , Aggarwal, Manik , Shmais, Manar, Bruining, David H. , Tariq, Raseen , Loftus, Edward V.

Mayo Clinic

American Journal of Gastroenterology | December 5, 2022 | Volume: 117 | Issue: 12S | Pages: S26-S26

10.14309/01.ajg.0000897904.38006.fd Get It

S27 Interobserver Agreement of Modified Paris Classification and Histology Prediction of Colorectal Lesions in Patients With Inflammatory Bowel Disease
Lennon, Ryan J. , Bruining, David H. , Kane, Sunanda, Leighton, Jonathan A. , Picco, Michael, Santiago, Priscila , Prabhu, Nayantara Coelho, Vinsard, Daniela Guerrero , East, James E. , Ebner, Derek W. , Kisiel, John B. , Loftus, Edward V. , Malik, Talha A. , Ramos, Guilherme Piovezani

Mayo Clinic

American Journal of Gastroenterology | December 5, 2022 | Volume: 117 | Issue: 12S | Pages: S7-S7

10.14309/01.ajg.0000897616.43383.78 Get It

Monogenic and Polygenic Contributions to Venous Thromboembolism (VTE) and Splanchnic Thrombosis in Patients (pts) with Pancreatic Cancer (PC)
Groha, Stefan , El‐Am, Edward , Bejjani, Antoine , Zarif, Talal El , Adib, Elio , Ng, Kimmie , Connors, Jean M. , Lee, Alfred Ian , Gusev, Alexander , Nassar, Amin H. , Mouhieddine, Tarek H. , Alaiwi, Sarah Abou

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 5525-5526

10.1182/blood-2022-163804 Get It

Pathogenic Germline Variants in a Prospective Multi-Center Cohort of Patients with Multiple Myeloma
Wiedmeier, Julia E. , Golafshar, Michael A. , Stewart, A. Keith, Samadder, Jewel, Golafshar, Michael , Wiedmeier-Nutor, Julia E , Kunze, Katie L. , Esplin, Edward D. , Nussbaum, Robert L. , Stewart, A. Keith, Bergsagel, P. Leif , Fonseca, Rafaël

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7162-7163

10.1182/blood-2022-167940 Get It

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry
Terebelo, Howard R. , Abonour, Rafat , Durie, Brian G.M. , Omel, James L., Narang, Mohit , Toomey, Kathleen, Rifkin, Robert M. , Gasparetto, Cristina, Yu, Edward, Anand, Jasmeet, Liu, Liang , Jou, Ying‐Ming, Jagannath, Sundar, Richter, Joshua , Ailawadhi, Sikander , Lee, Hans C. , Hardin, James W. , Wagner, Lynne I. , Omel, James, Gasparetto, Cristina , Jagannath, Sundar

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 8089-8091

10.1182/blood-2022-158627 Get It

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry
Abonour, Rafat , Durie, Brian G.M. , Gasparetto, Cristina, Narang, Mohit , Omel, James, Rifkin, Robert M. , Terebelo, Howard R. , Toomey, Kathleen, Slaff, Samantha, Danforth, Dailan, Chung, Weiyuan, Anand, Jasmeet, Yu, Edward, Tang, Derek, Jagannath, Sundar, Lee, Hans C. , Ailawadhi, Sikander , Gasparetto, Cristina , Hardin, James W. , Wagner, Lynne I. , Jagannath, Sundar

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 13256-13258

10.1182/blood-2022-158197 Get It

Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus: results from the COVAD study
Naveen, R, Nikiphorou, Elena , Joshi, Mrudula , Sen, Parikshit , Lindblom, Julius , Agarwal, Vishwesh , Tan, Ai Lyn , Salim, Babur , Ziadé, Nelly , Velikova, Tsvetelina , Gracia‐Ramos, Abraham Edgar , Kuwana, Masataka , Chinoy, Hector , Tehozol, Erick Adrian Zamora , Torre, Ignacio García-De La, Group, COVAD Study, Singh, Yogesh Preet , Ranjan, Rajiv , Pandya, Sapan C , Sharma, Aman , Manoj, Manesh , Patro, Pradeepta Sekhar , Ajmani, Sajal , Chowdhury, Abhra Chandra , Shenoy, Padnamabha, Bommakanti, Keerthi Talari, Shukla, Anuj , Pandey, Arun Kumar R, Kardeş, Sinan , Kim, Minchul , Pauling, John D , Wincup, Chris , Sambataro, Gianluca , Atzeni, Fabiola , Parisi, Simone , Bocci, Elena Bartoloni, Sainaghi, Pier Paolo , Orsolini, Giovanni , Angelis, Rossella De , Danielli, Maria Giovanna, Milchert, Marcin , Serrano, Jorge Rojas, Torre, Ignacio García-De La, Loarce‐Martos, Jesus , Prieto‐González, Sergio , Kuwana, Masataka, Nakashima, Ran , Sato, Shinji , Kimura, Naoki , Kaneko, Yuko , Tomaras, Stylianos, Aharonov, Or, Maurier, F. , Meyer, Alain , Nagy‐Vincze, Melinda , Limaye, Vidya, Needham, Merrilee , Srivastav, Nilesh , Hudson, Marie, Landon‐Cardinal, Océane , Shaharir, Syahrul Sazliyana , Zuleta, Wilmer Gerardo Rojas, Silva, José António Pereira, Gupta, Latika, Agarwal, Vikas , Parodis, Ioannis , Ravichandran, Naveen , Danieli, Maria Giovanna , Gupta, Latika , Naveen, R , Lilleker, James B , Tan, Ai Lyn , Ziade, Nelly , Gracia-Ramos, Abraham Edgar , Kuwana, Masataka , Day, Jessica , Distler, Oliver , Chinoy, Hector , Gupta, Latika , Parodis, Ioannis , Milchert, Marcin , Agarwal, Vikas , Joshi, Mrudula , Agarwal, Vishwesh , Salim, Babur , Velikova, Tsvetelina , Pauling, John D , Wincup, Chris , Zamora Tehozol, Erick Adrian , Sen, Parikshit , De Angelis, Rossella , Singh, Yogesh Preet , Day, Jessica , Makol, Ashima , Distler, Oliver , Traboco, Lisa S , Wibowo, Suryo Anggoro Kusumo , Rojas Serrano, Jorge , Torre, Ignacio García-De La, Group, COVAD Study, Barman, Bhupen , Jain, Avinash , Pilania, Rakesh Kumar , Gupta, Vikas , Kavadichanda, Chengappa G. , Phatak, Sanat B. , Goswami, Rudra P , Mathew, Ashish Jacob , Asranna, Ajay , Chandwar, Kunal , Cansu, Döndü Üsküdar , Chatterjee, Tulika , Cavagna, Lorenzo , Papa, Nicoletta Del , Govoni, Marcello , Bocci, Elena Bartoloni, Sebastiani, Gian Domenico , Fusaro, Enrico , Sebastiani, Marco , Quartuccio, Luca , Franceschini, Franco , Venerito, Vincenzo , Serrano, Jorge Rojas, Torre, Ignacio García-De La, Gil‐Vila, Albert , Gonzalez, Raquel Aranega, Kuwana, Masataka, Yoshida, Akira, Knitza, Johannes , Tomaras, Stylianos , Gromova, Margarita Aleksandrovna , Gheita, Tamer A. , Hmamouchi, Ihsane , Hoff, Leonardo Santos , Giannini, Margherita , Campagne, Julien , Langguth, Daman , Limaye, Vidya , Silva, José António Pereira, Fonseca, João Eurico , Zimba, Olena , Aggarwal, Rohit

Mayo Clinic

Rheumatology | November 21, 2022 | Volume: 62 | Issue: 7 | Pages: 2453-2463

10.1093/rheumatology/keac661 | PMID 36413073 Get It

Abstract Objective To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HC). Methods Data were captured through the COVID-19 Vaccination in Autoimmune Diseases (COVAD) questionnaire (March–December 2021). Multivariable regression models accounted for age, gender, ethnicity, vaccine type and background treatment. Results Among 9462 complete respondents, 583 (6.2%) were SLE patients (mean age: 40.1 years; 94.5% females; 40.5% Asian; 42.9% Pfizer-recipients). Minor AEs were reported by 83.0% of SLE patients, major by 2.6%, hospitalization by 0.2%. AE and hospitalization frequencies were similar between patients with active and inactive SLE. Rashes were more frequent in SLE patients vs HC (OR; 95% CI: 1.2; 1.0, 1.5), chills less frequent in SLE vs AIRDs (0.6; 0.4, 0.8) and nrAIDs (0.5; 0.3, 0.8), and fatigue less frequent in SLE vs nrAIDs (0.6; 0.4, 0.9). Pfizer-recipients reported higher overall AE (2.2; 1.1, 4.2) and injection site pain (2.9; 1.6, 5.0) frequencies than recipients of other vaccines, Oxford/AstraZeneca-recipients more body ache, fever, chills (OR: 2.5, 3.0), Moderna-recipients more body ache, fever, chills, rashes (OR: 2.6, 4.3). Hospitalization frequencies were similar across vaccine types. AE frequencies were similar across treatment groups, although chills were less frequent in antimalarial users vs non-users (0.5; 0.3, 0.9). Conclusion While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Pemmaraju, Naveen , Kantarjian, Hagop M. , Sweet, Kendra , Senapati, Jayastu , Konopleva, Marina , Frankel, Arthur E. , Gupta, Vikas , Ulrickson, Matthew L. , Gorak, Edward J., Bhatia, Sumeet, Budak-Alpdoǧan, Tülin , Mason, James R. , García‐Romero, María Teresa , López‐Santiago, Norma, Vachhani, Pankit , Lee, Sangmin , Blum, William , Walter, Roland B. , Bixby, Dale L. , Gojo, Ivana , Rampal, Raajit K. , Foran, James M. , Fathi, Amir T. , Hall, Aric C. , Jacoby, Meagan A., Mannis, Gabriel N. , Stein, Anthony S. , Rizzieri, David A. , Olin, Rebecca L. , Perl, Alexander E. , Schiller, Gary J. , Shami, Paul J. , Stone, Richard M. , Wieduwilt, Matthew J. , Vasu, Sumithira , Khoury, Joseph D. , Qazilbash, Muzaffar H. , Cuglievan, Branko , Madanat, Yazan F. , Kharfan‐Dabaja, Mohamed A. , Tallman, Martin S. , Dhakal, Prajwal , Senapati, Jayastu , Konopleva, Marina , Gupta, Vikas , Budak-Alpdogan, Tulin , Garcia-Romero, Maria Teresa , Cesarman-Maus, Gabriela , Vachhani, Pankit , Bhatt, Vijaya Raj , Walter, Roland B , Fathi, Amir T , Hall, Aric Cameron , Mims, Alice S , Rizzieri, David A , Perl, Alexander E , Strickland, Stephen Anthony , Daver, Naval , Guzmán, Mónica L. , Roboz, Gail J , Khoury, Joseph , Aung, Phyu P , Madanat, Yazan , Kharfan-Dabaja, Mohamed A , Pawlowska, Anna , Taylor, Justin , Dhakal, Prajwal , Lane, Andrew A , Kantarjian, Hagop , Wang, Eunice S. , Wilson, Nathaniel R. , Mesa, Ruben A. , Cesarman‐Maus, Gabriela , Bhatt, Vijaya Raj , Duvic, Madeleine , Lima, Marcos de , Lancet, Jeffrey E. , Daver, Naval , Ravandi, Farhad , Roboz, Gail J. , Lane, Andrew A.

Mayo Clinic

Blood | November 18, 2022 | Volume: 141 | Issue: 6 | Pages: 567-578

10.1182/blood.2022017865 | PMID 36399715 Get It

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC’s inaugural meetings are presented herein.
Health disparities in regional anesthesia and analgesia for the management of acute pain in trauma patients
Patton, John W., Burton, Brittany N. , Milam, Adam J. , Mariano, Edward R. , Gabriel, Rodney A. , Mariano, Edward R , Milam, Adam J

Mayo Clinic

International Anesthesiology Clinics | November 18, 2022 | Volume: 61 | Issue: 1 | Pages: 8-15

10.1097/aia.0000000000000382 | PMID 36398629 Get It